Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
SRF deletion results in earlier disease onset in a mouse model of amyotrophic lateral sclerosis
Jialei Song, Natalie Dikwella, Daniela Sinske, Francesco Roselli, Bernd Knöll
Jialei Song, Natalie Dikwella, Daniela Sinske, Francesco Roselli, Bernd Knöll
View: Text | PDF
Research Article Neuroscience

SRF deletion results in earlier disease onset in a mouse model of amyotrophic lateral sclerosis

  • Text
  • PDF
Abstract

Changes in neuronal activity modulate the vulnerability of motoneurons (MNs) in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). So far, the molecular basis of neuronal activity’s impact in ALS is poorly understood. Herein, we investigated the impact of deleting the neuronal activity–stimulated transcription factor (TF) serum response factor (SRF) in MNs of SOD1G93A mice. SRF was present in vulnerable MMP9+ MNs. Ablation of SRF in MNs induced an earlier disease onset starting around 7–8 weeks after birth, as revealed by enhanced weight loss and decreased motor ability. This earlier disease onset in SRF-depleted MNs was accompanied by a mild elevation of neuroinflammation and neuromuscular synapse degeneration, whereas overall MN numbers and mortality were unaffected. In SRF-deficient mice, MNs showed impaired induction of autophagy-encoding genes, suggesting a potentially new SRF function in transcriptional regulation of autophagy. Complementary, constitutively active SRF-VP16 enhanced autophagy-encoding gene transcription and autophagy progression in cells. Furthermore, SRF-VP16 decreased ALS-associated aggregate induction. Chemogenetic modulation of neuronal activity uncovered SRF as having important TF-mediating activity–dependent effects, which might be beneficial to reduce ALS disease burden. Thus, our data identify SRF as a gene regulator connecting neuronal activity with the cellular autophagy program initiated in degenerating MNs.

Authors

Jialei Song, Natalie Dikwella, Daniela Sinske, Francesco Roselli, Bernd Knöll

×

Figure 2

SRF deletion results in earlier disease onset in the SOD1 mouse model.

Options: View larger image (or click on image) Download as PowerPoint
SRF deletion results in earlier disease onset in the SOD1 mouse model.
(...
(A) Animals were analyzed weekly from 28 to 140 days of age. In each week, grip strength, NeuroScore, and body weight were determined twice, and inverted grid and pole tests were performed once. (B and C) In male mSOD1/Srf-KO mice (B) a decrease in body weight was observed earlier compared with mSOD1 mice. This was not observed in female mice (C). (D and E) The NeuroScore showed an earlier elevation in male mSOD1/Srf-KO mice compared with mSOD1 mice (D). A similar phenotype was observed in female mSOD1/Srf-KO mice (E). (F and G) The grip strength of the forelimbs was decreased in both male (F) and female (G) mSOD1/Srf-KO mice compared with mSOD1 mice starting at approximately 8 weeks. n values are indicated in B and C. Statistical testing was performed by 2-way ANOVA with Tukey corrections. *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts